RemeGen (HKG: 9995), a China-based pharmaceutical company, has appointed He Ruyi as its new Chief Strategy Officer, a role that marks his transition from Chief Medical Officer (CMO). He will continue to serve as a director of the company.
Dr. He Ruyi holds a Bachelor’s degree in Medicine and a Master’s degree in Internal Hematology from China Medical University. He completed his residency in internal medicine at Howard University School of Medicine in the United States, where he also earned a Doctor of Medicine degree and obtained practicing physician certificates in multiple states. With over 33 years of extensive experience in the medical and pharmaceutical sectors across China and the U.S., Dr. He brings nearly 20 years of decision-making and management expertise from his roles at the U.S. FDA and the Chinese National Medical Products Administration.- Flcube.com
